IN 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z https://t.co/zVHdVA2puZ

• AbbVie’s Skyrizi takes full-year TV ad spending crown yet again, with J&J’s Tre…

Mevalonate kinase deficiency (AKA hyper-IgD syndr-HIDS) is a rare autosomal recessive autoinflammatory dz of the MVK gene w/ exaggerated innate immunity & incr IL-1β production. Usually Dx in kids, milder forms of periodic fever syndrome have been seen in adults. https://t.co/0hAIz4JgY3

Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than placebo & equal to MTX regarding annual xray progression scores. Evidence in favor BUT failed to study monoRx vs Combo Rx https://t.co/eHdRPAcnkd https://t.co/1odwJjyL6A

• Effect of monotherapy with conventional synthetic disease-modifying anti-rheuma…

ACR Backs the Provider Reimbursement Stability Act The ACR thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and https://t.co/15xU3DGD34

In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and implications. 🎧 Listen here: https://t.co/ehPLdB4byb #Rheumatology #Autoimmunity #RNL2026 https://t.co/nLEPM3REi4

• RheumNow
• The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle | RheumN…

Adjunctive Prednisolone for Kawasaki Disease An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients. https://t.co/dS1uwufh69 https://t.co/wpxyOYXp8l

• Adjunctive Prednisolone for Kawasaki Disease | RheumNow

Leeds study of 63 pts w/ palindromic rheumatism (PR) progressed to Persistent IA (PIA) @ median 13.4 mos, hands predominating across flares. PIA developed in joints involved in PR flares in 71% of pts. @RA Dx, PR onset pts had signif higher swollen joints(4.1 vs 3.2) https://t.co/g2vjfVjDlK

Gabapentinoid use 2008-2018: worldwide there was an annual incr of +17.2% (from 4.2/d to 18.3/d per 10K pop. Highest gaba use in high income countries, 6X higher than lower income (40/d vs 6.1/d) https://t.co/jXjxNj1Uyz https://t.co/GmQJ3UGGw9

• Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a long…

If I cannot do great things, I can do small things in a great way.” - Martin Luther King, Jr

Retrospective observational study of IPAF (ILD w/ autoimmune) pts - from Mt Sinai ILD registry 791 - 14 Rx w/ rituximab vs 19 not. Betw group outcomes same: PFTs, O2 use, Infx, Resp admissions, mortality. RTX group recv more immunosuppressives. https://t.co/sle4a0JOFL https://t.co/rS69epQiif

• Frontiers | A single-center, observational, retrospective, case control study o…

A LESSON FOR GC OVERUSE: Inappropriate PPI use was Twice as successful w/ reduced w/ GP & Pt-facing intervention (15 vs 7%) vs usual care or GP-only intervention. Study of 1498 GPs, 34K pts https://t.co/QWW0VYVpzU https://t.co/X3V6NMawq2

• Deprescribing Intervention and Proton Pump Inhibitor Reduction in Primary Care

Potential new mechanism of MTX Effx - MTX polyglutamates accumulates in monocytes by D5, modulates transcriptional signature “non-classical monocyte”-assoc genes by Wk4, & predicts MTX responses https://t.co/0HtvWOczba https://t.co/oIs4V34hw3

• Monocytes from inflammatory arthritis patients accumulate methotrexate and thei…

Malignancies Not Increased with Biologic Therapies The risk of malignancy in RA patients receiving biologic agents was evaluated by metanalysis of RCTs and found no significant increased risk of malignancy compared with other DMARDs or with placebo. https://t.co/ZEO4jP5RwA https://t.co/C1YeTSh7ZN

• Malignancies Not Increased with Biologic Therapies | RheumNow

Rheumatoid Arthritis Faculty Panel Q&A This expert panel from https://t.co/4UQlqwujiR 2026 brings together leading faculty to address real-world challenges in RA care, offering practical insights you can apply immediately in practice. 🎧 Listen here: https://t.co/LOiUuia852 https://t.co/REvpPJv0O8

• RheumNow
• Rheumatoid Arthritis Faculty Panel Q&A | RheumNow